REDWOOD CITY, California, July 16 --
Pulmonx, an emerging leader in interventional pulmonology and in the
development of device therapies for the treatment of emphysema announced today
that Michael A. Baker has joined the company as President and CEO and that he
has been elected as a member of its board of directors.
We are very excited that Mike will be leading our company as we begin to
commercialize our proprietary medical device therapies for these important
indications, said Dr. Rodney Perkins, Founder and Chairman of the Board. The
strategic and leadership skills he has developed over the course of his career
will be of great value to Pulmonx.
Mr. Baker’s professional career comprises over two decades of executive
experience in the medical device industry with much of it directly focused on
the development and commercialization of new device technologies and
device-based therapies. His career includes assignments with ArthroCare
Corporation, where he served as the President and CEO for over 11 years, and
with Medtronic, where he served for over 8 years in executive and general
management assignments in both the United States and Europe. Mr. Baker holds an
M.B.A. from the University of Chicago and a B.S. from the United States Military
Academy at West Point.
The addition of Mike Baker follows a series of strategic developments including
the receipt of FDA marketing clearance for a key new product and the completion
of a successful acquisition. In early July, the company received FDA marketing
clearance for the Chartis System, an assessment tool which allows physicians to
make regional assessments of lung function, including quantifying inter-lobar
airflow in the lungs, known as collateral ventilation. Recent research suggests
that the presence of collateral ventilation may have an important impact on the
effectiveness of Endobronchial Lung Volume Reduction (ELVR) therapy(1, 2). By
helping physicians to identify the presence of collateral ventilation, the
Chartis System may enable them to better identify patients who could benefit
from endobronchial valve therapy.
The FDA clearance follows Pulmonx’s recent acquisition of Emphasys
Medical, which added Emphasys’ Zephyr family of endobronchial valves for
ELVR to the company’s proprietary portfolio of diagnostic and therapeutic
products. The Zephyr endobronchial valves are already CE marked and commercially
available in many countries around the world. Pulmonx intends to begin
international commercialization of the Chartis system as soon as it receives the
This is an exciting time for all of us here at Pulmonx, commented Mike Baker,
President and CEO of Pulmonx. With the completion of the acquisition of Emphasys
Medical, Inc. and 510K clearance of our Chartis System, Pulmonx is poised to
become a leader in the treatment of pulmonary disorders such as severe
emphysema. These new technologies have the potential to cost-effectively improve
the health of literally millions of patients globally and I’m extremely
enthusiastic about the opportunity to lead this outstanding team as we work to
commercialize these breakthrough products and build a strong franchise in
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing
and marketing minimally-invasive medical devices and technologies for the
diagnosis and treatment of pulmonary disorders. Pulmonx is venture funded by
Montreux Ventures, MedVenture Associates, DeNovo Ventures, Latterell Ventures,
Covidien Ventures and Posco Bioventures.
(1) Aljuri N, Freitag L. Validation and pilot clinical study of a new
bronchoscopic method to measure collateral ventilation prior to endobronchial
lung volume reduction. J Appl Physiol. 2009;106:774-783.
(2) Fessler HE. Collateral damage assessment for endobronchial lung volume
reduction. J Appl Physiol. 2009;106:755-756.
SOURCE: Pulmonx Corporation
Rich Ferrick of Pulmonx Corporation, +1-650-216-0108, email@example.com